JP Morgan Private Wealth Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$754K	Sell	14,484 -284	-2%	-$16.5K	﹤0.01%	1083
2023 Q2	$935K	Sell	14,768 -1,057	-7%	-$65.9K	﹤0.01%	782
2023 Q1	$857K	Buy	15,825 +2,631	+20%	+$127K	﹤0.01%	1239
2022 Q4	$698K	Buy	13,194 +3,306	+33%	+$166K	﹤0.01%	1323
2022 Q3	$460K	Buy	9,888 +5,485	+125%	+$287K	﹤0.01%	1499
2022 Q2	$251K	Buy	4,403 +154	+4%	+$8.73K	﹤0.01%	1739
2022 Q1	$260K	Buy	+4,249	New	+$221K	﹤0.01%	1808

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Private Wealth Advisors's ITCI Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 1.9% in Q3 2023, selling an estimated $16.5K and leaving 14,484 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #1083.

JP Morgan Private Wealth Advisors first reported a position in ITCI in Q1 2022 and has held it in 7 quarters since. The position peaked at $935K in Q2 2023. 292 funds tracked by Wall St. Rank hold ITCI as of Q3 2023.

JP Morgan Private Wealth Advisors held 14,484 shares of Intra-Cellular Therapies Inc. worth $754K as of Q3 2023.
JP Morgan Private Wealth Advisors sold 284 Intra-Cellular Therapies Inc. shares in Q3 2023, an estimated $16.5K.
Intra-Cellular Therapies Inc. made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1083 holding.
JP Morgan Private Wealth Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and has held it in 7 quarters since.
JP Morgan Private Wealth Advisors's Intra-Cellular Therapies Inc. position peaked at $935K in Q2 2023.
292 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.